These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

680 related items for PubMed ID: 22592369

  • 1. Anti-JC virus antibodies in a large German natalizumab-treated multiple sclerosis cohort.
    Trampe AK, Hemmelmann C, Stroet A, Haghikia A, Hellwig K, Wiendl H, Goelz S, Ziegler A, Gold R, Chan A.
    Neurology; 2012 May 29; 78(22):1736-42. PubMed ID: 22592369
    [Abstract] [Full Text] [Related]

  • 2. A second-generation ELISA (STRATIFY JCV™ DxSelect™) for detection of JC virus antibodies in human serum and plasma to support progressive multifocal leukoencephalopathy risk stratification.
    Lee P, Plavina T, Castro A, Berman M, Jaiswal D, Rivas S, Schlain B, Subramanyam M.
    J Clin Virol; 2013 Jun 29; 57(2):141-6. PubMed ID: 23465394
    [Abstract] [Full Text] [Related]

  • 3. Risk of natalizumab-associated progressive multifocal leukoencephalopathy.
    Bloomgren G, Richman S, Hotermans C, Subramanyam M, Goelz S, Natarajan A, Lee S, Plavina T, Scanlon JV, Sandrock A, Bozic C.
    N Engl J Med; 2012 May 17; 366(20):1870-80. PubMed ID: 22591293
    [Abstract] [Full Text] [Related]

  • 4. Anti-JC virus antibodies: implications for PML risk stratification.
    Gorelik L, Lerner M, Bixler S, Crossman M, Schlain B, Simon K, Pace A, Cheung A, Chen LL, Berman M, Zein F, Wilson E, Yednock T, Sandrock A, Goelz SE, Subramanyam M.
    Ann Neurol; 2010 Sep 17; 68(3):295-303. PubMed ID: 20737510
    [Abstract] [Full Text] [Related]

  • 5. The effect of plasma exchange on serum anti-JC virus antibodies.
    Subramanyam M, Plavina T, Khatri BO, Fox RJ, Goelz SE.
    Mult Scler; 2013 Jun 17; 19(7):912-9. PubMed ID: 23232602
    [Abstract] [Full Text] [Related]

  • 6. Anti-JC virus seroprevalence in a Finnish MS cohort.
    Kolasa M, Hagman S, Verkkoniemi-Ahola A, Airas L, Koivisto K, Elovaara I.
    Acta Neurol Scand; 2016 May 17; 133(5):391-7. PubMed ID: 26347001
    [Abstract] [Full Text] [Related]

  • 7. Changes to anti-JCV antibody levels in a Swedish national MS cohort.
    Warnke C, Ramanujam R, Plavina T, Bergström T, Goelz S, Subramanyam M, Kockum I, Rahbar A, Kieseier BC, Holmén C, Olsson T, Hillert J, Fogdell-Hahn A.
    J Neurol Neurosurg Psychiatry; 2013 Nov 17; 84(11):1199-205. PubMed ID: 23463870
    [Abstract] [Full Text] [Related]

  • 8. Study of the anti-JCV antibody levels in a Spanish multiple sclerosis cohort.
    Dominguez-Mozo MI, Rus M, Santiago JL, Izquierdo G, Casanova I, Galan V, Garcia-Martinez MA, Arias-Leal AM, García-Montojo M, Pérez-Pérez S, Arroyo R, Alvarez-Lafuente R.
    Eur J Clin Invest; 2017 Feb 17; 47(2):158-166. PubMed ID: 28036121
    [Abstract] [Full Text] [Related]

  • 9. Risk stratification for progressive multifocal leukoencephalopathy in patients treated with natalizumab.
    Sørensen PS, Bertolotto A, Edan G, Giovannoni G, Gold R, Havrdova E, Kappos L, Kieseier BC, Montalban X, Olsson T.
    Mult Scler; 2012 Feb 17; 18(2):143-52. PubMed ID: 22312009
    [Abstract] [Full Text] [Related]

  • 10. Anti-John Cunnigham virus antibody prevalence in multiple sclerosis patients: baseline results of STRATIFY-1.
    Bozic C, Richman S, Plavina T, Natarajan A, Scanlon JV, Subramanyam M, Sandrock A, Bloomgren G.
    Ann Neurol; 2011 Nov 17; 70(5):742-50. PubMed ID: 22162056
    [Abstract] [Full Text] [Related]

  • 11. Anti-JCV antibody prevalence in a French cohort of MS patients under natalizumab therapy.
    Outteryck O, Ongagna JC, Duhamel A, Zéphir H, Collongues N, Lacour A, Fleury MC, Berteloot AS, Blanc F, Giroux M, Vermersch P, de Sèze J.
    J Neurol; 2012 Nov 17; 259(11):2293-8. PubMed ID: 22527227
    [Abstract] [Full Text] [Related]

  • 12. Immune responses to JC virus in patients with multiple sclerosis treated with natalizumab: a cross-sectional and longitudinal study.
    Jilek S, Jaquiéry E, Hirsch HH, Lysandropoulos A, Canales M, Guignard L, Schluep M, Pantaleo G, Du Pasquier RA.
    Lancet Neurol; 2010 Mar 17; 9(3):264-72. PubMed ID: 20117055
    [Abstract] [Full Text] [Related]

  • 13. JC-virus seroconversion in multiple sclerosis patients receiving natalizumab.
    Outteryck O, Zéphir H, Salleron J, Ongagna JC, Etxeberria A, Collongues N, Lacour A, Fleury MC, Blanc F, Giroux M, de Seze J, Vermersch P.
    Mult Scler; 2014 Jun 17; 20(7):822-9. PubMed ID: 24072722
    [Abstract] [Full Text] [Related]

  • 14. Anti-JC virus antibody levels in serum or plasma further define risk of natalizumab-associated progressive multifocal leukoencephalopathy.
    Plavina T, Subramanyam M, Bloomgren G, Richman S, Pace A, Lee S, Schlain B, Campagnolo D, Belachew S, Ticho B.
    Ann Neurol; 2014 Dec 17; 76(6):802-12. PubMed ID: 25273271
    [Abstract] [Full Text] [Related]

  • 15. Does risk stratification decrease the risk of natalizumab-associated PML? Where is the evidence?
    Cutter GR, Stüve O.
    Mult Scler; 2014 Sep 17; 20(10):1304-5. PubMed ID: 24812045
    [Abstract] [Full Text] [Related]

  • 16. Natalizumab treatment for multiple sclerosis: updates and considerations for safer treatment in JCV positive patients.
    Nali LH, Moraes L, Fink MC, Callegaro D, Romano CM, Oliveira AC.
    Arq Neuropsiquiatr; 2014 Dec 17; 72(12):960-5. PubMed ID: 25465776
    [Abstract] [Full Text] [Related]

  • 17. Natalizumab treatment perturbs memory- and marginal zone-like B-cell homing in secondary lymphoid organs in multiple sclerosis.
    Planas R, Jelčić I, Schippling S, Martin R, Sospedra M.
    Eur J Immunol; 2012 Mar 17; 42(3):790-8. PubMed ID: 22144343
    [Abstract] [Full Text] [Related]

  • 18. Anti-JC virus antibody prevalence in a multinational multiple sclerosis cohort.
    Olsson T, Achiron A, Alfredsson L, Berger T, Brassat D, Chan A, Comi G, Eraksoy M, Hegen H, Hillert J, Jensen PE, Moiola L, Myhr KM, Oturai A, Schippling S, Siva A, Sorensen PS, Trampe AK, Weber T, Potts J, Plavina T, Paes D, Subramanyam M, Wiendl H, Dib H, Uren D, Hemmer B, Buck D.
    Mult Scler; 2013 Oct 17; 19(11):1533-8. PubMed ID: 23459571
    [Abstract] [Full Text] [Related]

  • 19. Longitudinal JCV serology in multiple sclerosis patients preceding natalizumab-associated progressive multifocal leukoencephalopathy.
    Vennegoor A, van Rossum JA, Polman CH, Wattjes MP, Killestein J.
    Mult Scler; 2015 Oct 17; 21(12):1600-3. PubMed ID: 25662344
    [Abstract] [Full Text] [Related]

  • 20. PML risk stratification using anti-JCV antibody index and L-selectin.
    Schwab N, Schneider-Hohendorf T, Pignolet B, Spadaro M, Görlich D, Meinl I, Windhagen S, Tackenberg B, Breuer J, Cantó E, Kümpfel T, Hohlfeld R, Siffrin V, Luessi F, Posevitz-Fejfár A, Montalban X, Meuth SG, Zipp F, Gold R, Du Pasquier RA, Kleinschnitz C, Jacobi A, Comabella M, Bertolotto A, Brassat D, Wiendl H.
    Mult Scler; 2016 Jul 17; 22(8):1048-60. PubMed ID: 26432858
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 34.